NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, Forecast & News

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.07) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.04. The biotechnology company earned $20.86 million during the quarter, compared to the consensus estimate of $16.27 million. Rigel Pharmaceuticals had a negative return on equity of 52.74% and a negative net margin of 56.84%. During the same period in the previous year, the company posted ($0.14) earnings per share. View Rigel Pharmaceuticals' Earnings History.

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Rigel Pharmaceuticals.

Rigel Pharmaceuticals will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Rigel Pharmaceuticals issued an update on its fourth quarter 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15.4-15.4 million, compared to the consensus revenue estimate of $15.14 million.

4 brokers have issued 12-month price targets for Rigel Pharmaceuticals' shares. Their forecasts range from $7.00 to $8.00. On average, they expect Rigel Pharmaceuticals' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 250.5% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.

Media stories about RIGL stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rigel Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Rigel Pharmaceuticals.

Some companies that are related to Rigel Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Geron (GERN), Terra Tech (TRTC), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Fate Therapeutics (FATE), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Athersys (ATHX) and Progenics Pharmaceuticals (PGNX).

Rigel Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (13.63%), Tamarack Advisers LP (3.43%), State Street Corp (2.19%), Palo Alto Investors LP (2.11%), Goldman Sachs Group Inc. (1.86%) and Renaissance Technologies LLC (1.78%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Dean L Schorno, Eldon C Mayer III, Nelson Cabatuan and Raul R Rodriguez. View Institutional Ownership Trends for Rigel Pharmaceuticals.

RIGL stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., FMR LLC, Rhenman & Partners Asset Management AB, Granite Investment Partners LLC, Geode Capital Management LLC, Russell Investments Group Ltd., California Public Employees Retirement System and Palo Alto Investors LP. View Insider Buying and Selling for Rigel Pharmaceuticals.

RIGL stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Panagora Asset Management Inc., Ikarian Capital LLC, Bank of Montreal Can, Tamarack Advisers LP and State Street Corp. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Dean L Schorno, Eldon C Mayer III and Raul R Rodriguez. View Insider Buying and Selling for Rigel Pharmaceuticals.

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RIGL stock can currently be purchased for approximately $2.14.

Rigel Pharmaceuticals has a market capitalization of $358.69 million and generates $44.51 million in revenue each year. The biotechnology company earns $-70,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.View Additional Information About Rigel Pharmaceuticals.

The official website for Rigel Pharmaceuticals is http://www.rigel.com/.

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]